In a global first, Uganda’s Ministry of Health, the World Health Organization (WHO) and other partners today launched a first-ever clinical efficacy trial for a vaccine from Ebola from the Sudan ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

In India, the "Big Four" - the spectacled cobra, common krait, Russell's viper, and saw-scaled viper - cause many deaths ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...